Locations:
Search IconSearch
December 9, 2025/Cancer/News & Insight

Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

church bus tour

Black Americans have a significantly higher incidence, severity and mortality from venous thromboembolism (VTE) compared to other racial and ethnic groups. Despite this elevated risk, awareness and education about VTE remain limited in many Black communities.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

To address this knowledge gap, the National Blood Clot Alliance launched the Black Lives Advocating for Clot Knowledge (B.L.A.C.K) Church Bus Tour, which partnered with faith-based institutions in southeastern Black communities. This program aimed to empower individuals to recognize VTE risk factors and symptoms, know when to seek prompt care and learn about preventive actions.

A bold approach

Featuring a bright-red bus with signage describing VTE symptoms, the campaign educated individuals to take steps to reduce the risk of VTE and to recognize the condition when it occurs. The bus tour included four churches in Charlotte, NC, Marietta, GA and Memphis, TN. The tour incorporated educational sessions and the distribution of educational materials.

Researchers collected pre- and post-event surveys to assess changes in knowledge resulting from the program. The findings were presented at the 2025 ASH annual meeting.

“The NBCA bus tour campaign underscores the value of culturally tailored educational interventions in addressing gaps in VTE awareness,” says Dana Angelini, MD, a physician in the Classical Hematology team at Cleveland Clinic Cancer Institute.

Program demographics

More than 450 people participated in the events across the southeastern U.S. The majority of participants were between 61-70 years old, and 73.1% were female. Most participants identified as Black, non-Hispanic.

Roughly 89% participants said they had not personally experienced a blood clot and they did not have a friend or family member who had experienced one.

Advertisement

Increasing awareness

Wilcoxon signed-rank test was used to compare section and total survey scores before and after the program. Analysis of the pre- and post-surveys found a statistically significant increase in awareness across 16 knowledge domains. In addition to gaining knowledge about symptoms and treatments, the overwhelming majority of participants also strongly agreed to make lifestyle changes to reduce their risk of contracting VTE.

Additionally, most participants reported their intention to share this knowledge in the community. “This finding demonstrates the power that community education has to spread awareness to those who are in front of us and beyond,” says Dr. Angelini.

What’s next

Based on the success of the program, the National Blood Clot Alliance is working on a “2.0” version of the bus tour, and hopes to make this an annual endeavor. The plan is to continue to raise awareness in the hopes of fostering earlier intervention and risk mitigation and ultimately reduce VTE-associated mortality rates. “This initiative highlights the importance of meeting people where they are, in environments where they feel comfortable, and providing them with trusted health education.,” says Dr. Angelini.

Advertisement

Related Articles

Researcher with microscope
June 26, 2026/Cancer

Testosterone May Offer Anti-Tumor Activity in Glioblastoma

Research findings offer clues for improving disease outcomes in men

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Dr. Kamath & colleagues in the lab
June 2, 2026/Cancer/News & Insight

Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response

Study serves as ‘cautionary tale’ for physicians tempted to rely on liquid biopsy results alone

Ad